SCYNEXIS Completes BREXAFEMME NDA Transfer to GSK, Enabling Antifungal Drug Relaunch
Key Insights
SCYNEXIS has completed the transfer of BREXAFEMME's New Drug Application to GSK, allowing the pharmaceutical giant to initiate FDA discussions for the antifungal drug's relaunch.
BREXAFEMME (ibrexafungerp) is FDA-approved for treating vulvovaginal candidiasis (search) and reducing recurrent infections, representing the first in SCYNEXIS's novel "fungerps" antifungal platform.
Following relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones plus low to mid single-digit royalties from GSK.
SCYNEXIS, Inc. has completed the transfer of the BREXAFEMME (ibrexafungerp) New Drug Application to GSK, marking a significant milestone that positions the antifungal drug for relaunch in the U.S. market. The biotechnology company announced on November 19, 2025, that GSK can now initiate regulatory interactions with the U.S. Food and Drug Administration to discuss the relaunch strategy for treating vulvovaginal candidiasis (search).
Financial Terms and Future Revenue Potential
The completed NDA transfer establishes a lucrative revenue stream for SCYNEXIS following the drug's relaunch. The company stands to receive up to $145.5 million in annual net sales milestones, along with royalties in the low to mid single-digit range, net of payments to Merck (search). This arrangement provides SCYNEXIS with what CEO David Angulo described as "a significant future source of non-dilutive capital."
BREXAFEMME's Therapeutic Profile
BREXAFEMME represents the first drug in SCYNEXIS's proprietary "fungerps" antifungal platform, addressing a critical need in treating difficult-to-treat and drug-resistant infections (search). The FDA has approved the ibrexafungerp tablets for two key indications: treatment of vulvovaginal candidiasis (search) (VVC) and reduction in the incidence of recurrent VVC. The drug targets both standard vulvovaginal candidiasis and refractory vulvovaginal candidiasis (search) (rVVC) cases.
Strategic Partnership and Market Positioning
"We are pleased to announce this important milestone for SCYNEXIS," said David Angulo, M.D., President and Chief Executive Officer. "With the transfer of the BREXAFEMME NDA now complete, GSK will be able to initiate regulatory interactions with the U.S. Food and Drug Administration (FDA) to discuss the relaunch of BREXAFEMME for vulvovaginal candidiasis (search) (VVC) and refractory vulvovaginal candidiasis (search) (rVVC) in the U.S. market."
The partnership with GSK leverages the pharmaceutical giant's commercial capabilities and regulatory expertise to bring BREXAFEMME back to market. GSK remains committed to the relaunch strategy, providing SCYNEXIS with a pathway to monetize its innovative antifungal technology without the operational burden of direct commercialization.
Broader Antifungal Pipeline
Beyond BREXAFEMME, SCYNEXIS continues developing additional antifungal assets from its novel fungerps class. The company's pipeline includes SCY-247, currently progressing through clinical, pre-clinical, and discovery phases. This broader platform positions SCYNEXIS as a pioneer in addressing the growing challenge of drug-resistant fungal infections affecting millions of patients worldwide.